• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Statistics and Research Methods  • Health Care Reform  • Comparative Effectiveness  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Comment on "Impact of the ALLHAT/JNC7 Dissemination Project on Thiazide-Type Diuretic Use"

Jerry Avorn, MD

Arch Intern Med. 2010;170(10):858-860.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The connection between clinical research and typical patient care presents a frustrating paradox. Many well-documented advances in therapy are not adopted widely or quickly, whereas other, unimpressive new treatments are taken up in epidemic proportions, their use often fueled by marketing campaigns that are far more powerful than the medicines being advertised.¹ As a result, patients are frequently exposed to new therapies that may be less effective or less safe than the older regimens they replace. For example, ezetimibe (Zetia and Vytorin; Merck/Shering-Plough Pharmaceuticals, North Wales, Pennsylvania) may not prevent atherosclerosis as well as the statin-only regimens it displaces for many patients; rosiglitazone maleate (Avandia; GlaxoSmithKline, Philadelphia, Pennsylvania) increases the risk of cardiovascular disease in patients with diabetes mellitus; and rofecoxib (Vioxx; Merck & Co Inc, Whitehouse Station, New Jersey) nearly doubled the occurrence of myocardial infarction or stroke in patients who took it, while offering no . . . [Full Text of this Article]

AUTHOR INFORMATION
Author Affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Impact of the ALLHAT/JNC7 Dissemination Project on Thiazide-Type Diuretic Use
Randall S. Stafford, L. Kay Bartholomew, William C. Cushman, Jeffrey A. Cutler, Barry R. Davis, Glenna Dawson, Paula T. Einhorn, Curt D. Furberg, Linda B. Piller, Sara L. Pressel, Paul K. Whelton, and for the ALLHAT Collaborative Research Group
Arch Intern Med. 2010;170(10):851-858.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nursing Science and Evidence-Based Practice
Titler
West J Nurs Res 2011;33:291-295.
 

'Bench To Behavior': Translating Comparative Effectiveness Research Into Improved Clinical Practice
Avorn and Fischer
Health Aff (Millwood) 2010;29:1891-1900.
ABSTRACT | FULL TEXT